Two Nobel Prize winners just lost a patent ruling to a team that published their key paper seven months later. Let that sink in.

Why the CRISPR ruling matters more than you think

On March 26, 2026, the U.S. Patent Trial and Appeal Board reaffirmed that the Broad Institute, MIT, and Harvard were the first to invent the use of CRISPR gene editing in eukaryotic cells. That means human cells. That means the cells that matter for medicine.

I think this ruling is genuinely good news for science, even if it feels wrong on the surface. Here is why: it forces clarity. Ambiguity in biotech patents kills investment and delays cures. A decade of legal fog has already slowed down who can license what, and patients with sickle cell disease do not have time for that fog.

Here is the story in plain terms. Jennifer Doudna of UC Berkeley and Emmanuelle Charpentier of Umeå University published the foundational CRISPR paper in June 2012. They showed the tool worked in a test tube. Seven months later, Feng Zhang at the Broad Institute published proof it worked inside actual mammalian cells. The PTAB ruled that getting it to work in living cells was not an obvious step from the test tube work.

The Nobel Prize and the patent office disagree. Who is right?

Doudna and Charpentier won the 2020 Nobel Prize in Chemistry for inventing CRISPR. The Nobel committee said they invented it. The U.S. patent system said someone else gets the commercial rights to the most important application. These two things can both be true, and that is not a contradiction. It is a feature of how patent law actually works.

The counterpunch argument goes like this: Doudna and Charpentier conceived the idea first, filed first, and the Broad team only succeeded after seeing their work. I do not fully buy that. The PTAB looked at this twice, and even after a federal appeals court sent it back for a do-over in 2025, the board reached the same conclusion. Conception without a working demonstration in the relevant cell type is not enough under U.S. patent law.

“After considering the Federal Circuit's remand and CVC's and Broad's briefing on priority, we determine that the preponderance of the evidence shows that the CVC inventors did not conceive of an embodiment of Count 1 before the Broad inventors' actual reduction to practice on 5 October 2012.”

— U.S. Patent Trial and Appeal Board, March 26, 2026

That is a brutal sentence for Berkeley. But it is also a precise one.

The real prize is already in patients' bodies

While lawyers argued for a decade, the science kept moving. In December 2023, the FDA approved Casgevy as the first CRISPR therapy ever cleared for human use. It treats sickle cell disease in patients 12 and older. Sickle cell disease affects approximately 100,000 people in the U.S. and has caused suffering for generations, disproportionately in Black communities.

I remember reading about sickle cell as a kid and thinking it was one of those diseases medicine had simply given up on. Casgevy is proof that was wrong. The therapy edits a patient's own stem cells outside the body, then returns them. In clinical trials, 29 out of 31 evaluable patients were free from severe pain crises for at least 12 consecutive months.

The bad edge here is real and worth naming: Casgevy costs $2.2 million per patient. That is not a cure for most people. It is a cure for people whose insurance or government will pay. The patent structure that just got reaffirmed feeds directly into that pricing reality.

Patents are not the enemy. Monopoly pricing is.

Here is where I land. The Broad ruling is legally correct and scientifically defensible. What is broken is not the patent system itself but the pricing system that sits on top of it. The Broad Institute has 31 granted CRISPR patents in the U.S. alone. That is enormous leverage. The question is whether they use it to extract maximum rent or to enable broad access.

The Broad has actually called for a patent pool and cross-licensing framework with Berkeley. That is smart policy. If both sides stop the war and pool their IP, every biotech developer gets cleaner access, prices face more competition, and patients win. The ruling gives Broad the leverage to make that deal on favorable terms. The question is whether they will.

Would you trust a $3 billion research institution to voluntarily lower its licensing fees when it just won the biggest biotech patent fight in history?

Science won even if the Nobel winners lost in court

UC Berkeley still holds more than 60 U.S. CRISPR patents covering compositions and methods across all cell types. This ruling does not erase Doudna and Charpentier from the story. It just means the most commercially valuable slice of the technology belongs to Cambridge, Massachusetts.

The science itself is unstoppable. CRISPR therapies are now in clinical trials for high cholesterol, hereditary blindness, advanced cancers, and rare genetic conditions. The 2026 Breakthrough Prize ceremony in Los Angeles just honored advances in gene editing alongside dark matter and quantum physics. The field is not slowing down for any court ruling.

The patent war was always a sideshow to the actual revolution. The revolution is happening in patients' bone marrow right now. That is the only scoreboard that matters.